SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccinationArticle Published on 2023-01-012023-07-11 Journal: EBioMedicine [Category] COVID19(2023년), [키워드] convalescent COVID-19 mucosal immunity Nasal antibody SARS-CoV-2 immunity SARS-CoV-2 variants vaccination. [DOI] 10.1016/j.ebiom.2022.104402 PMC 바로가기
Repertoires of SARS-CoV-2 epitopes targeted by antibodies vary according to severity of COVID-19코로나19 중증도에 따라 항체 표적 SARS-CoV-2 에피토프 레퍼토리 달라Article Published on 2022-12-012022-09-11 Journal: Virulence [Category] COVID19(2023년), SARS, 진단, 치료법, [키워드] antibodies antibody Antigen association Asymptomatic asymptomatic individual asymptomatic infection Betacoronavirus betacoronavirus Community convalescent correlated COVID-19 COVID-19 severity develop diagnosed diagnostics disease severity domains Epitopes Evidence evidence of finding FIVE five groups HKU1 Hospitalization IgG IgGs Immunity immunogenic immunogenic peptide individual Infection less MERS-CoV nucleocapsid protein Nucleocapsid proteins OC43 participant pathogenic pathogenic mechanisms peptide peptide array peptides pilot study predicted Protein RBDs reaction Receptor binding domain Region repertoire SARS-CoV RBD SARS-CoV RBDs SARS-CoV-2 SARS-CoV-2 epitope SARS-CoV-2 epitopes seroconverted Seroprevalence seroprevalence. severity severity of COVID-19 symptomatic symptomatic COVID-19 symptomatic infection therapeutic therapeutic antibodies Vaccines Viral with COVID-19 without symptoms [DOI] 10.1080/21505594.2022.2073025 PMC 바로가기 [Article Type] Article
Neutralization of five SARS-CoV-2 variants of concern by convalescent and BBIBP-CorV vaccinee serumArticle Published on 2022-12-012023-07-10 Journal: Virologica Sinica [Category] COVID19(2023년), [키워드] BBIBP-CorV vaccine convalescent neutralization SARS-CoV-2 variants of concern (VOCs). [DOI] 10.1016/j.virs.2022.10.006 PMC 바로가기
A 1-year longitudinal study on COVID-19 convalescents reveals persistence of anti-SARS-CoV-2 humoral and cellular immunityCOVID-19 회복기에 대한 1년 종단 연구는 항 SARS-CoV-2 체액성 및 세포성 면역의 지속성을 보여줍니다Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] 1-year after infection anti-SARS-CoV-2 humoral antibody antibody durability. caused CD4 CD8 CD8 T cell CD8 T cell responses Cell cellular immunity central memory circulating antibodies circulating antibody Cohort convalescent COVID-19 COVID-19 convalescent COVID-19 patient disease disease severity effective IgG level immune Immune components immune memory immune protection Immunity induce Infection information Kinetics maintain memory memory B memory B cell Memory responses memory T cells omicron Omicron variant peptide peptide pool persistence protective immunity provide RBD IgG Re-infection recorded response reveal SARS-CoV-2 SARS-CoV-2 circulating antibodies SARS-COV-2 infection subject Symptom T cell T cell response T cell responses T cells tested the RBD the SARS-CoV-2 variant [DOI] 10.1080/22221751.2022.2049984 PMC 바로가기 [Article Type] Article
Phase II/III trial of hyperimmune anti-COVID-19 intravenous immunoglobulin (C-IVIG) therapy in severe COVID-19 patients: study protocol for a randomized controlled trialArticle Published on 2022-11-082022-11-16 Journal: Trials [Category] SARS, 변종, [키워드] adaptive anti-COVID-19 IVIG antivirals clinical evidence clinical trial collected convalescent convalescent plasma COVID-19 cumulative death Efficacy eligibility criteria evaluate Health hyperimmune immunization immunomodulators intravenous Intravenous immunoglobulin low dose monoclonal antibodies Neutralizing non-specific novel Novel coronavirus outcome Passive passive immunization Patient phase Pneumonia polyclonal polyclonal antibodies Pooled convalescent plasma Potential treatment Randomized Randomized controlled trial receive Recovered COVID-19 patients reported SARS CoV-2 SARS CoV-2. SARS-CoV-2 sealed Secondary outcomes severe COVID-19 severe COVID-19 patient severe COVID-19 patients Standard of care Steroids Study protocol therapeutic option therapy treat Treatment Trial variant variants of concern virus virus particles World Health Organization [DOI] 10.1186/s13063-022-06860-2 PMC 바로가기
Reduced humoral but stable cellular SARS-CoV-2-specific immunity in liver transplant recipients in the first year after COVID-19Article Published on 2022-11-022022-11-15 Journal: PLoS ONE [Category] SARS, 진단, 치료기술, [키워드] anti-Nucleocapsid IgG anti-SARS-CoV-2 anti-SARS-CoV-2 IgG antibody Antigen booster vaccination cellular cellular immunity Cohort Concentration convalescent COVID-19 detectable domain Endemic humoral IFN-γ IgG immune response Immunity Immunoglobulin Immunosuppressed Immunosuppression immunosuppressive individual liver Liver transplantation membrane nucleocapsid Prevalence protective immunity reactivity Receptor binding domain recipient remained retrieved robust SARS-CoV-2 significantly increased Spike protein stimulated T cell T cell response therapy vaccination [DOI] 10.1371/journal.pone.0276929 PMC 바로가기
Antibody response and intra-host viral evolution after plasma therapy in COVID-19 patients pre-exposed or not to B-cell-depleting agentsArticle Published on 2022-11-012022-11-15 Journal: British Journal of Haematology [Category] SARS, 진단, [키워드] anti-CD20 anti-CD20 therapy Anti-spike anti-Spike IgG antibody antibody kinetics B-cell clinical care clinical status clinical symptom Complete contribute convalescent convalescent plasma COVID-19 patient Decline donors eligible evaluated Follow-up hospitalized COVID-19 patients humoral Humoral immunity IgG Immune escape Immunocompromised Immunocompromised patients Immunoglobulin impair lymphopenia majority management mRNA-based vaccine mRNA-based vaccine plasma mutation rate Patient patients treated plasma receiving SARS-CoV-2 SARS-CoV-2 viral load SARS-CoV-2-specific antibodies severity spike mutations survival therapy titre viral control viral evolution virus clearance WHO whole-genome sequencing Whole-genome sequencing. World Health Organization [DOI] 10.1111/bjh.18450 PMC 바로가기
Deep immunophenotyping reveals biomarkers of multisystemic inflammatory syndrome in children in a Latin American cohortArticle Published on 2022-11-012022-11-15 Journal: The Journal of Allergy and Clinical Immunology [Category] SARS, 바이오마커, 진단, [키워드] acute respiratory syndrome Biomarker Biomarkers CCL5 Cell cellular response characterized chemokine children Chilean clinical clinical feature Cohort Complication convalescent coronavirus COVID-19 CXCL10 CXCL8 Cytokine storm deep degranulation disease dysregulation elevated enzyme-linked immunosorbent enzyme-linked immunospot flow cytometry gastrointestinal involvement humoral identify IL-10 IL-18 IL-6 immune dysregulation immune response Immunity Inflammation Inflammatory intestinal inflammation laboratory biomarker Latin life-threatening Ligand MIS-C mononuclear cell MOST motif multisystemic multisystemic inflammatory syndrome in children. natural killer neutralizing antibody neutralizing antibody assays NK cell NK cell deficiency occur organ Patient patients predict representing reveal robust severe multisystemic severity Shock significantly stools susceptibility sustained syndrome T-cell activation underlie was increased was performed [DOI] 10.1016/j.jaci.2022.09.006 PMC 바로가기
Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infectionArticle Published on 2022-11-012022-11-15 Journal: Journal of Clinical Virology [Category] SARS, 변종, 진단, 치료기술, [키워드] antibody Antibody neutralization Antibody titre B.1.1.529 BNT162b2 booster Breakthrough infection convalescent CoronaVac COVID-19 detectable dose elicited geometric GMT Immune escape individual Infection less natural infection neutralization neutralizing antibody Neutralizing antibody response of BNT162b2 omicron Omicron, Neutralization plaque reduction neutralization PRNT reduction relative SARS-CoV-2 susceptible Transmissibility vaccinated individual vaccination Vaccine vaccine. Vaccines virus viruses VoC wild- type WT virus [DOI] 10.1016/j.jcv.2022.105273 PMC 바로가기
Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccinationArticle Published on 2022-10-282022-11-15 Journal: Science Immunology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] Antibody Response B.1.617.2 BAL Blood booster vaccination Breakthrough infection Bronchoalveolar lavage fluid cellular immunity circulating Combination convalescent COVID-19 COVID-19 vaccine D614G Delta demonstrated effective elicit hospitalized patients humoral immune response Immunity immunization individual induce Infection mRNA vaccination mucosal neutralizing antibody Neutralizing antibody response neutralizing antibody responses offer omicron Reinfection respiratory respiratory tract response robust SARS-CoV-2 severe disease significantly lower Support T cell T cell response the SARS-CoV-2 vaccinated individuals variant variants of concern virus VOCs with COVID-19 [DOI] 10.1126/sciimmunol.add4853 PMC 바로가기